eISSN: 2449-9315
ISSN: 1234-8279
Pharmacotherapy in Psychiatry and Neurology/Farmakoterapia w Psychiatrii i Neurologii
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
 
1/2022
vol. 38
 
Share:
Share:
more
 
 
Review article

Possibilities of therapeutic action of cannabinoids in neurodegenerative diseases

Anna A. Kaszyńska
1

1.
University of Social Sciences and Humanities;
Uniwersytet Humanistycznospołeczny SWPS
Farmakoterapia w Psychiatrii i Neurologii 2022, 38 (1), 49–58
Online publish date: 2022/08/02
Article file
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
PlumX metrics:
 
1. Al-Chalabi A, Hardiman O. The epidemiology of ALS: a conspiracy of genes, environment, and time. Nat. Rev. Neurol. 2013; 9: 617-28.
2. Ashton CH, Moore PB, Gallagher P, Young AH. Cannabinoids in bipolar affective disorder: A review and discussion of their therapeutic potential. Journal of Psychopharmacology 2005; 19(3): 293-300.
3. Bartoli F, Riboldi I, Bachi B, Calabrese A, Moretti F, Crocamo C, Carrà G. Efficacy of Cannabidiol for Δ-9-Tetrahydrocannabinol-Induced Psychotic Symptoms, Schizophrenia, and Cannabis Use Disorders: A Narrative Review. Journal of Clinical Medicine 2021; 10(6), 1303.
4. Battistella G, Fornari E, Annoni J-M, Chtioui H, Dao K, Fabritius et al. Long-Term Effects of Cannabis on Brain Structure. Neuropsychopharmacology 2014; 39(9): 2041-2048.
5. Bilsland LG, Dick JRT, Pryce G, Petrosino S, Di Marzo V, Baker D et al. Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice. FASEB J. 2006; 20: 1003-5.
6. Bińkowska A, Brzezicka A. Wpływ marihuany na aktywność elektryczną mózgu. Kosmos 2020; 69(1): 219-232.
7. Blázquez C, Chiarlone A, Sagredo O, Aguado T, Pazos MR, Resel E i wsp. Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington’s disease. Brain 2011; 134: 119-36.
8. Bolla K, Eldreth D, Matochik J, Cadet J. Neural substrates of faulty decision-making in abstinent marijuana users. NeuroImage 2005; 26(2): 480-492.
9. Borgan F, Beck K, Butler E, McCutcheon R, Veronese M, Vernon A, Howes OD. The effects of cannabinoid 1 receptor compounds on memory: A meta-analysis and systematic review across species. Psychopharmacology 2019; 236(11): 3257-3270.
10. Chye Y, Solowij N, Suo C, Batalla A, Cousijn J, Goudriaan AE. et al. Orbitofrontal and caudate volumes in cannabis users: A multi-site mega-analysis comparing dependent versus non-dependent users. Psychopharmacology 2017; 234(13): 1985-1995.
11. Costa B, Trovato AE, Comelli F, Giagnoni G, Colleoni M. The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain. European Journal of Pharmacology 2007; 556(1-3): 75-83.
12. Cousijn J, Wiers RW, Ridderinkhof KR, van den Brink W, Veltman DJ, Goudriaan AE. Grey matter alterations associated with cannabis use: Results of a VBM study in heavy cannabis users and healthy controls. NeuroImage 2012; 59(4): 3845-3851.
13. van den Elsen GAH, Ahmed AIA, Verkes R-J, Kramers C, Feuth T, Rosenberg PB et al. Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: A randomized controlled trial, Neurology 2015; 84: 2338-2346.
14. van den Elsen GA, Tobben L, Ahmed AI, Verkes RJ, Kramers C, Marijnissen RM et al. Effects of tetrahydrocannabinol on balance and gait in patients with dementia: A randomised controlled crossover trial. J. Psychopharmacol. 2017; 31: 184-191.
15. Espejo-Porras F, García-Toscano L, Rodríguez-Cueto C, Santos-García I, de Lago E, Fernandez-Ruiz J. Targeting glial cannabinoid CB2 receptors to delay the progression of the pathological phenotype in TDP-43 (A315T) transgenic mice, a model of amyotrophic lateral sclerosis. Br. J. Pharmacol 2019; 176(10): 1585-1600.
16. van de Giessen E, Weinstein JJ, Cassidy CM, Haney M, Dong Z, Ghazzaoui R. et al. Deficits in striatal dopamine release in cannabis dependence. Molecular Psychiatry 2017; 22(1): 68-75.
17. Ferland J-MN, Hurd YL. Deconstructing the neurobiology of cannabis use disorder. Nature Neuroscience 2020; 23(5), 600-610.
18. Galán-Ganga M, Rodríguez-Cueto C, Merchán-Rubira J, Hernández F, Ávila J, Posada-Ayala M, Lanciego JL, Luengo E, Lopez MG, Rábano A, Fernández-Ruiz J, Lastres-Becker I. Cannabinoid receptor CB2 ablation protects against TAU induced neurodegeneration. Acta Neuropathologica Communications 2021; 9(1): 90.
19. Guttman Z, Moeller SJ, London ED. Neural underpinnings of maladaptive decision-making in addictions. Pharmacology Biochemistry and Behavior 2018; 164: 84-98.
20. Hardiman O, van den Berg LH, Kiernan MC. Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat. Rev. Neurol. 2011; 7: 639-649.
21. He J-T, Li X-Y, Yang L, Zhao X. Astroglial connexins and cognition: Memory formation or deterioration? Bioscience Reports 2020; 40(1), BSR20193510.
22. Hill KP, Palastro MD, George TP. Therapeutic cannabis use in 2018: Where do we stand? The Lancet Psychiatry 2019; 6(2): 88-89.
23. Huzard D, Rappeneau V, Meijer OC, Touma C, Arango-Lievano, M., Garabedian, MJ., Jeanneteau, F. Experience and activity-dependent control of glucocorticoid receptors during the stress response in large-scale brain networks. Stress 2021; 24(2): 130-153.
24. Kim SH, Yang JW, Kim KH, Kim JU, Yook TH. A Review on Studies of Marijuana for Alzheimer’s Disease-Focusing on CBD, THC. Journal of Pharmacopuncture 2019; 22(4): 225-230.
25. Koenders L, Lorenzetti V, de Haan L, Suo C, Vingerhoets W, van den Brink W. et al. Longitudinal study of hippocampal volumes in heavy cannabis users. Journal of Psychopharmacology 2017; 31(8): 1027-1034.
26. Koob GF, Volkow ND. Neurobiology of addiction: A neurocircuitry analysis. The Lancet Psychiatry 2016; 3(8), 760-773.
27. de Lago E, FR-J, Moreno-Martet M, Espejo-Porras F. Endocannabinoids and amyotrophic lateral sclerosis, in: Fattore L. (Ed.), Cannabinoids in Neurologic and Mental Disease, Elsevier 2015: 99-124.
28. Laprairie RB, Warford JR, S. Hutchings S, Robertson GS, Kelly MEM, Denovan-Wright EM. The cytokine and endocannabinoid systems are co-regulated by NF-κB p65/RelA in cell culture and transgenic mouse models of Huntington’s disease and in striatal tissue from Huntington’s disease patients. J. Neuroimmunol. 2014; 267: 61-72.
29. Leroy C, Karila L, Martinot J-L, Lukasiewicz M, Duchesnay E, Comtat C et al. Striatal and extrastriatal dopamine transporter in cannabis and tobacco addiction: A high-resolution PET study: DAT availability in addictions. Addiction Biology 2012; 17(6): 981-990.
30. Mievis S, Blum D, Ledent C. Worsening of Huntington disease phenotype in CB1 receptor knockout mice. Neurobiol. Dis. 2011; 42: 524-9.
31. Millington C, Sonego S, Karunaweera N, Rangel A, Aldrich-Wright JR, Campbell IL et al. Chronic Neuroinflammation in Alzheimer’s Disease: New Perspectives on Animal Models and Promising Candidate Drugs. BioMed Research International 2014; 2014: 1-10.
32. Morgan CJ, Freeman TP, Schafer GL, Curran HV. Cannabidiol Attenuates the Appetitive Effects of Δ9-Tetrahydrocannabinol in Humans Smoking Their Chosen Cannabis. Neuropsychopharmacology 2010; 35(9): 1879-1885.
33. Muetzel RL, Marjańska M, Collins PF, Becker MP, Valabrègue R, Auerbach EJ et al. In vivo 1H magnetic resonance spectroscopy in young-adult daily marijuana users. NeuroImage: Clinical 2013; 2: 581-589.
34. O’Donnell BF, Skosnik PD, Hetrick WP, Fridberg DJ. Decision Making and Impulsivity in Young Adult Cannabis Users. Frontiers in Psychology 2021; 12.
35. Pasquarelli N, Engelskirchen M, Hanselmann J, Endres S, Porazik C, Bayer H., et al. Evaluation of monoacylglycerol lipase as a therapeutic target in a transgenic mouse model of ALS., Neuropharmacology 2017; 124: 157-169.
36. Patricio F, Morales-Andrade AA, Patricio-Martínez A, Limón ID. Cannabidiol as a Therapeutic Target: Evidence of its Neuroprotective and Neuromodulatory Function in Parkinson’s Disease. Frontiers in Pharmacology 2020; 11.
37. Pietropaolo S, Bellocchio L, Ruiz-Calvo A, Cabanas M, Du, M. Guzmán M et al. Chronic cannabinoid receptor stimulation selectively prevents motor impairments in a mouse model of Huntington’s disease. Neuropharmacology 2015; 89: 368-74.
38. Pintor A, Tebano MT, Martire A, Grieco R, Galluzzo M, Scattoni ML et al. The cannabinoid receptor agonist WIN 55,212-2 attenuates the effects induced by quinolinic acid in the rat striatum. Neuropharmacology 2006; 51: 1004-12.
39. Prescot AP, Locatelli AE, Renshaw PF, Yurgelun-Todd DA. Neurochemical alterations in adolescent chronic marijuana smokers: A proton MRS study. NeuroImage 2011; 57(1): 69-75.
40. Ramírez BG, Blázquez C, Gómez del Pulgar T, Guzmán M, de Ceballos ML. Prevention of Alzheimer’s disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J. Neurosci. 2005; 25: 1904-13.
41. Renton AE, Majounie E, Waite A, Simón-Sánchez J, Rollinson S, Gibbs JR et al. A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS- FTD. Neuron. 2011; 72: 257-268.
42. Ross CA, Kronenbuerger M, Duan W, Margolis RL. Mechanisms underlying neurodegeneration in Huntington disease: applications to novel disease-modifying therapies. Handb. Clin. Neurol. 2017; 144: 15-28.
43. Rüb U, Seidel K, Heinsen H, Vonsattel JP, den Dunnen WF, Korf HW, Huntington’s disease (HD): the neuropathology of a multisystem neurodegenerative disorder of the human brain. Brain Pathol. 2016; 26: 726-740.
44. Saft C, Djamshidian A, Heim B, Seppi K. Cannabinoids for Treatment of Dystonia in Huntington’s Disease. 7.
45. Sagar KA, Gruber SA. Interactions between recreational cannabis use and cognitive function: Lessons from functional magnetic resonance imaging. Annals of the New York Academy of Sciences 2019; 1451(1): 42-70.
46. Sagredo O, Pazos MR, Valdeolivas S, Fernandez-Ruiz J. Cannabinoids: novel medicines for the treatment of Huntington’s disease. Recent Pat. CNS Drug Discov 2012; 7 41-8.
47. Sampaio C, Borowsky B, Reilmann R. Clinical trials in Huntington’s disease: Interventions in early clinical development and newer methodological approaches. Mov. Disord. 2014; 29: 1419-28.
48. Schuster RM, Hoeppner SS, Evins AE, Gilman JM. Early onset marijuana use is associated with learning inefficiencies. Neuropsychology 2016; 30(4): 405-415.
49. Sharman MJ, Verdile G, Kirubakaran S, Parenti C, Singh A, Watt G, Karl T, Chang D, Li CG, Münch G. Targeting Inflammatory Pathways in Alzheimer’s Disease: A Focus on Natural Products and Phytomedicines. CNS Drugs 2019; 33(5): 457-480.
50. Solowij N, Jones KA, Rozman ME, Davis SM, Ciarrochi J, Heaven PCL, Lubman DI, Yücel M. Verbal learning and memory in adolescent cannabis users, alcohol users and non-users. Psychopharmacology 2011; 216(1): 131-144.
51. Stella N. Genetic rescue of CB1 receptors on medium spiny neurons prevents loss of excitatory striatal synapses but not motor impairment in HD mice. Neurobiol. Dis. 2014; 71: 140-50.
52. Volkow ND, Baler RD, Compton WM, Weiss SRB. Adverse Health Effects of Marijuana Use. New England Journal of Medicine 2014; 370(23): 2219-2227.
53. Witting A, Weydt P, Hong S, Kliot M, Moller T, Stella N. Endocannabinoids accumulate in spinal cord of SOD1 G93A transgenic mice. J. Neurochem. 2004; 89: 1555-7.
54. Zuccato C, Cattaneo E. Huntington’s disease. Handb. Exp. Pharmacol. 2014; 220: 357-409.
55. Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG. Psychopharmacology C Springer-Verlag 1982; 76: 245-250.
Quick links
© 2023 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.